Filing Flows › Fulgent Genetics (FLGT) › Capital expenditures
Fulgent Genetics (FLGT) capital expenditures by quarter
Fulgent Genetics' capital expenditures were $1.8M in Q3 2026 (third quarter 2026), -66% from Q1 2026. Over the last 3 quarters it ranged from $1.8M (Q3 2026) to $6.0M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.8M | -66% | -70% |
| Q1 2026 | $5.2M | -14% | — |
| Q3 2025 | $6.0M | — | — |
Q3 2026 at a glance
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.
Questions
What is Fulgent Genetics' capital expenditures?
Fulgent Genetics' capital expenditures were $1.8M in Q3 2026 (third quarter 2026), -66% from Q1 2026.
How has Fulgent Genetics' capital expenditures changed?
Over the last 3 quarters it ranged from $1.8M (Q3 2026) to $6.0M (Q3 2025).